Nebilan

Nebivolol

Method of action: Antianginal, Antiarrhythmic, Antihypertensive, Beta Blocking Agents, Hypotensive

Treatment option: Hypertension, Heart Failure

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Nebilan

What is Nebilan? The Foundational Identity

Property	Description
Active Ingredient	Nebivolol (as the hydrochloride salt)
Form	Tablet
Pharmacological Class	Beta-Adrenergic Blocking Agent (Third-Generation Beta-blocker)
Key Property	Cardioselective and Nitric Oxide-Mediated Vasodilatory
Origin	Synthetic

Nebilan is a prescription-only medicinal product administered orally, defined by its active ingredient, Nebivolol hydrochloride. It is a synthetic, single-ingredient product supplied in the form of a tablet.

The Definition of Nebilan: Active Ingredient and Class

Nebivolol is a beta-adrenergic blocking agent, or beta-blocker, typically used for the treatment of high blood pressure. Specifically, it is a third-generation beta-blocker and a highly cardioselective agent, meaning it preferentially targets the beta1-adrenergic receptors predominantly located in the heart. This high degree of cardioselectivity is a key differentiating factor, especially at standard therapeutic levels, which helps minimize interaction with beta2-receptors located in the lungs. The medicine is designated a third-generation beta-blocker due to its unique dual pharmacological profile, which extends beyond simple receptor blockade.

Nebivolol’s Unique Dual Action and General Purpose

Nebivolol stands apart from many conventional beta-blockers by demonstrating a distinct dual mechanism: it reduces heart activity while actively promoting vasodilation. The compound is a racemate containing the mathbfD-enantiomer, which mediates the selective heart-slowing effect, and the mathbfL-enantiomer, which enhances the vasodilating property. This action involves stimulating the release of nitric oxide (NO) from the blood vessel lining, a mechanism for improving endothelial function and reducing systemic vascular resistance. The fundamental, overarching purpose of Nebilan is to stabilize cardiac activity and facilitate the efficient, sustained reduction of high blood pressure, functioning as a vital antihypertensive agent.

What side effects are possible with Nebilan?

Possible Side Effects and Safety Information

The official safety profile for Nebilan (nebivolol) classifies adverse reactions based on their frequency of occurrence and the organ system affected, as documented in government regulatory sources. These classifications structure the understanding of the medicine’s risk profile.

Frequency-Classified Adverse Reactions

Adverse reactions are grouped into categories based on reporting frequency, which may vary depending on the condition treated (e.g., hypertension versus heart failure):

Classification	Examples of Reactions (Label-Documented)
Common (1% to 10%)	Headache, Dizziness, Fatigue, Paresthesia, Constipation, Diarrhea, Nausea, Edema.
Uncommon (0.1% to 1%)	Nightmares, Depression, Insomnia, Vertigo, Impotence, Bronchospasm, Hypotension, Aggravation of heart failure (in hypertension patients).
Very Rare (<0.01%)	Syncope (fainting), Aggravation of Psoriasis.

Serious Safety Considerations and Restrictions

Regulatory labels highlight specific safety constraints and potential serious adverse reactions:

Risk Upon Discontinuation: Abrupt cessation of Nebilan is contraindicated, particularly in patients with coronary artery disease, due to the documented risk of severe events, including myocardial infarction (heart attack), severe angina, and ventricular arrhythmias. Therapy must be gradually reduced, or tapered.
Contraindications: Nebilan must not be used in patients with certain severe pre-existing conditions, including severe bradycardia (very slow heart rate), heart block greater than first degree, cardiogenic shock, decompensated cardiac failure, and severe hepatic impairment.
Special Population Safety Notes: The medication may mask signs of hypoglycemia in patients with diabetes or symptoms of hyperthyroidism. A dose adjustment is required for patients with severe renal impairment.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory documentation for Nebilan (Nebivolol) defines overdose by its potential for severe, life-threatening cardiovascular manifestations, necessitating immediate professional medical intervention. The documented clinical presentations reflect the consequences of excessive beta-adrenergic blockade.

The most frequent and serious documented signs of overdose include severe bradycardia (abnormally slow heart rate), excessive hypotension (profoundly low blood pressure), heart block, and the onset of acute cardiac failure. Other documented manifestations may include bronchospasm, hypoglycemia, and in severe cases, central nervous system effects such as coma or circulatory failure leading to cardiogenic shock.

Immediate medical help must be sought for any suspected overdose, as regulatory authorities classify this situation as potentially dangerous. The regulatory approach dictates that management is primarily symptomatic and supportive, as no specific antidote is known. Supportive measures often include close monitoring, administering intravenous fluids and vasopressors to manage severe hypotension, and using beta-agonists to pharmacologically reverse the profound beta-blocking effects. Due to the seriousness of the documented manifestations, continuous close observation is required until clinical stability is achieved.

Therapeutic Uses of Nebilan

What Nebilan Treats: Main Uses and Benefits

Nebilan (nebivolol) is primarily used in the management of two major cardiovascular conditions: essential hypertension (high blood pressure) and as part of combination therapy for stable, chronic heart failure in elderly patients (age 70 and over). In these contexts, the medication is used to lower blood pressure and support cardiac function.

This medication is applied in addressing symptoms related to systemic imbalance by helping to lower elevated pressure readings, which create noticeable physiological strain on the circulatory system. It is often used during phases when symptoms become more noticeable and supportive symptom management is appropriate.

“This treatment assists with maintaining functional stability and supports the patient during difficult episodes by easing discomfort associated with the condition.”

A key benefit is its role in supporting the management of conditions associated with heightened cardiovascular risk. By helping to keep pressure stable and supporting heart function, this treatment may assist in addressing the long-term risk of organ damage caused by chronic stress. It contributes to easing the overall symptom load and helps improve day-to-day comfort.

Quick Fact: Support for Managing Blood Pressure Nebilan is applied in addressing symptom clusters that create noticeable physiological strain in conditions presenting with systemic discomfort.

Eligibility and Restrictions for Use

This section outlines the eligibility criteria for Nebilan (nebivolol) as documented in official regulatory sources, such as the FDA and EMA. Use is established and approved for adults with hypertension, and for older adults (age 70 and over) with stable, chronic heart failure.

Absolute Contraindications

Nebilan is contraindicated (must not be used) in patients with severe cardiac issues, including severe bradycardia, heart block greater than first degree, cardiogenic shock, and decompensated cardiac failure. It is also prohibited for patients with sick sinus syndrome (unless a pacemaker is present), severe hepatic impairment (Child-Pugh Class C), and known hypersensitivity to the product.

Restricted Use Populations

Use is restricted or requires caution in specific populations. For those with moderate hepatic impairment or severe renal impairment, treatment must begin with an adjusted initial dose. The medicine is not established and not recommended for the pediatric population (under 18 years of age). For pregnant women, use is not recommended during the second and third trimesters, and it is not recommended for women who are breastfeeding.

What should I know about interactions with other medicines?

Nebilan’s (nebivolol) official interaction profile is defined by pharmacokinetic and pharmacodynamic interactions documented in regulatory sources.

Pharmacokinetic Interactions

Nebivolol is metabolized by the CYP2D6 enzyme. Co-administration with strong CYP2D6 inhibitors significantly increases the drug’s exposure and plasma concentrations. Specific interacting medicines listed in regulatory documents include fluoxetine, propafenone, paroxetine, and quinidine. This increase in systemic exposure may necessitate close patient monitoring and is relevant to individuals classified as CYP2D6 Poor Metabolizers, who naturally have substantially increased nebivolol exposure.

Pharmacodynamic Interactions

Interactions that affect heart function are common. Combining Nebilan with agents that slow atrioventricular (AV) conduction or depress myocardial function, such as non-dihydropyridine calcium channel blockers (verapamil or diltiazem type), increases the risk of severe bradycardia. Additive effects on heart rate also occur with digitalis glycosides (e.g., digoxin).

Administration-Related Constraints

Specific timing constraints are required when co-administering clonidine. Nebilan must be discontinued for several days before the gradual tapering of clonidine to mitigate the risk of a severe hypertensive rebound upon withdrawal. The use of certain anesthetic agents that depress the heart requires close monitoring during surgery. Regarding food and other substances, official documentation notes that Nebilan's absorption is not significantly affected by food, but alcohol may potentiate the hypotensive effects.

Mechanism of Action

Nebilan, a racemic mixture, acts via a dual pharmacodynamic mechanism. Primarily, its D-enantiomer functions as a highly selective antagonist at myocardial beta1-adrenergic receptors. This molecular interaction blocks the binding of endogenous catecholamines, thereby suppressing the Gs protein-coupled receptor signaling cascade. The intracellular consequence is a reduction in adenylyl cyclase activity, leading to decreased intracellular cAMP and blunted protein kinase A (PKA) signaling. System-level physiological consequences include negative chronotropy (reduced heart rate) and negative inotropy (decreased myocardial contractility), which diminish cardiac output.

Secondly, the L-enantiomer of Nebilan acts as an agonist at beta3-adrenergic receptors located on the vascular endothelium. Activation of this receptor subtype stimulates the Gs protein signaling pathway, leading to the activation of endothelial nitric oxide synthase (eNOS). This enhanced enzymatic activity increases the production of nitric oxide (NO) within the vascular endothelial cells. The subsequent diffusion of NO into the adjacent vascular smooth muscle cells promotes the activation of guanylyl cyclase, increasing cyclic GMP (cGMP) levels. This downstream cascade results in dephosphorylation of myosin light chains and ultimately, vasodilation, which modulates systemic peripheral vascular resistance.

Dosage and Administration Information

Nebilan is a prescription product administered orally as a tablet and is generally taken once daily at the same time each day, a consistent pattern established to maintain stable levels. The tablets may be consumed with or without food. The complete antihypertensive effect typically stabilizes within two to four weeks following the start of treatment or a dose change.

The dosing regimen requires a mathbfgradual approach to adjustment. Dose increases, if necessary for essential hypertension, should occur no more frequently than in mathbftwo-week intervals. The standard initial dose is mathbf5 mg once daily for hypertension.

Condition	Standard Starting Dose (Once Daily)	Maximum Labeled Dose
Essential Hypertension	mathbf5 mg	mathbf40 mg
Chronic Heart Failure (Elderly ge 70)	mathbf1.25 mg	mathbf10 mg

Dosing adjustments are mandated for patients with certain pre-existing conditions. For individuals with severe renal impairment or moderate hepatic impairment, the recommended initial dose is reduced to mathbf2.5 mg once daily, and titration must proceed cautiously. Use is not recommended for severe hepatic impairment. If a dose is missed, the patient should resume the normal routine with the next scheduled dose and must not double the amount.

To conclude the use of this medicine, therapy must not be stopped abruptly. The protocol requires the dose to be gradually tapered over a period of approximately mathbfone to two weeks to complete the regimen. Furthermore, the initiation and every dose increase for Chronic Heart Failure must be performed under the close supervision of an experienced physician.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Nebilan (Nebivolol)

This overview describes the types of clinical studies that have been conducted for Nebilan, focusing only on the official research base and the populations that were evaluated, without offering any clinical advice or interpretation of results.

Evidence from Studies for Essential Hypertension (High Blood Pressure)

Research exploring Nebilan for essential hypertension is based on short-to-intermediate term Randomized Controlled Trials (RCTs). These studies examined adult participants with mild to moderate high blood pressure, typically over a few weeks up to 12 weeks. Findings from these trials and subsequent systematic reviews reported differences in blood pressure measurements between the Nebivolol group and the placebo group. Comparative research with other established blood pressure medications examined the observed changes in blood pressure relative to patterns seen with other treatments.

However, there is limited information for long-term outcomes from large, dedicated RCTs that track major cardiovascular events, such as heart attack or stroke, specifically comparing Nebivolol against all other major antihypertensive classes over many years.

Evidence from Studies for Stable, Chronic Heart Failure

The research foundation for Nebilan's use in chronic heart failure conditions is mainly derived from a single, large, dedicated RCT (the SENIORS trial). This study focused on outcomes reflecting functional imbalance in a specific population: elderly patients aged 70 years and older.

The primary trial documented the reported frequency patterns of a composite endpoint, which monitored both all-cause death and hospitalizations related to cardiovascular events, between the study groups. Studies also monitored other functional measures, such as heart pump function. The all-cause death rate, when measured separately from the hospitalizations, was reported as not distinguishable between the study groups in the main trial's primary analysis.

What Remains Uncertain in the Research Landscape

Current research provides context on what has been observed, but data are still emerging in several areas:

Heart Failure Subgroups: While the major heart failure evidence for the composite outcome is concentrated in the elderly population (70), data for other age groups remain insufficient from comparable large, dedicated trials.
Comparative Evidence: Direct head-to-head RCTs designed to prove superior effectiveness of Nebivolol over other standard beta-blockers for heart failure comparative evidence is lacking.

Frequently Asked Questions (FAQ)

Common questions about Nebilan (FAQ)

Q: What should I do if I take too much Nebilan (overdose)?

If an overdose of Nebilan is suspected, it is recommended to immediately contact a poison control center or seek emergency medical attention. Official regulatory documents describe possible symptoms of overdose, which primarily relate to severe effects on the heart and blood pressure. Medical management generally involves supportive measures determined by a clinician based on the patient's condition.

Q: Can Nebilan be crushed or split?

Official product information describes Nebilan as a tablet that is administered orally. Regulatory labels do not typically provide explicit instructions regarding crushing or splitting the tablets for consumption. The medicine should be taken as supplied and directed by the healthcare professional who prescribed it.

Q: Does Nebilan cause weight gain?

According to official drug labels, unusual weight gain or weight gain has been reported as an adverse reaction in clinical experience. This effect is generally considered an infrequent or less common side effect associated with the medication. Concerns about changes in weight should be discussed with a healthcare provider.

Q: Is it safe to drive while taking Nebilan?

Regulatory information indicates that Nebilan may cause side effects such as dizziness or fatigue. These effects could potentially affect an individual's ability to drive or operate complex machinery. Individuals should be aware of their personal reaction to the medication before engaging in activities that require alertness and concentration.

How should Nebilan be stored and disposed of?

Storage and Disposal Requirements

Nebilan (nebivolol) must be stored and handled according to specific conditions defined by regulatory authorities to ensure product quality and safety.

Storage Parameter	Regulatory Requirement
Temperature	Store at Controlled Room Temperature, typically 20 C to 25 C (68 F to 77 F), acknowledging permitted excursions. Do not freeze.
Protection	Keep the medicine away from excess heat, moisture, and direct light.
Packaging	Must be kept in the original container or package and remain tightly closed until use to protect from moisture.
Child Safety	Keep this medicine strictly out of the sight and reach of children.
Disposal	Do not dispose of via wastewater or household waste. Consult a pharmacist to learn how to discard unused or expired product in accordance with local environmental regulations.